Sirt3 Sirtuin 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Sirt3 Sirtuin 3 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes. [1]
SIRT3 is a member of the sirtuin family of NAD+-dependent deacetylases, primarily localized to mitochondria. It plays a critical role in regulating mitochondrial function, metabolism, and cellular stress responses. [2]
| Attribute | Value | [3]
|-----------|-------| [4]
| Gene Symbol | SIRT3 |
| Full Name | Sirtuin 3 |
| Chromosomal Location | 11p15.5 |
| NCBI Gene ID | 23410 |
| OMIM | 604479 |
| Ensembl ID | ENSG00000142092 |
| UniProt | Q9NWU1 |
SIRT3 is the primary mitochondrial deacetylase, regulating key metabolic enzymes and proteins involved in:
SIRT3 is the primary mitochondrial deacetylase and plays a critical protective role in dopaminergic neurons. SIRT3 protects dopaminergic neurons from mitochondrial dysfunction through:
Complex I protection: SIRT3 deacetylates complex I subunits to maintain electron transport chain function—directly relevant to PD given the well-established complex I deficiency in PD substantia nigra. PMID: 25933439
MnSOD activation: SIRT3 deacetylates manganese superoxide dismutase (MnSOD), enhancing its enzymatic activity to reduce oxidative stress in dopaminergic neurons.
IDH2 activation: SIRT3 deacetylates isocitrate dehydrogenase 2 (IDH2), increasing NADP+/NADPH production crucial for reducing glutathione and combating oxidative stress.
The Sirtuin Pathway Dysfunction Hypothesis in Parkinson's Disease identifies SIRT3 as a key mitochondrial guardian whose dysfunction contributes to PD pathogenesis:
Genetic evidence: SIRT3 rs3729620 variant associated with PD risk in Chinese cohort. PMID: 28552878
Biochemical evidence: SIRT3 expression reduced in PD patient brain tissue and models.
Preclinical evidence: SIRT3 overexpression protects against MPTP-induced dopaminergic neurodegeneration. PMID: 25933439
SIRT3 activation is a promising therapeutic approach for PD:
| Approach | Status | Notes |
|---|---|---|
| SRT1720 | Preclinical | SIRT3-selective activator |
| NAD+ precursors (NR, NMN) | Phase 2 | Increases SIRT3 activity indirectly |
| Honokiol | Preclinical | Natural SIRT3 activator |
| Gene therapy (AAV-SIRT3) | Research | Direct SIRT3 delivery |
The NADAPT Study (NCT06162013) evaluates NAD+ precursor supplementation that indirectly enhances SIRT3 activity through increased NAD+ substrate.
See the Sirtuin Pathway Dysfunction Validation Experiment for detailed study design including SIRT3-targeted interventions.
SIRT3 is highly expressed in:
| Approach | Status | Notes |
|---|---|---|
| SIRT3 activators | Preclinical | Honokiol, SRT1720 derivatives |
| NAD+ boosters | Clinical | Increases SIRT3 activity indirectly |
| Gene therapy | Research | AAV-mediated SIRT3 delivery |
Sirt3 Sirtuin 3 plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Sirt3 Sirtuin 3 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.